Cargando…

Impact of Fixed Combination of Metformin and Pioglitazone on Insulin Resistance of Patients with Type 2 Diabetes: Results of a Randomized Open-Label Study

AIM: To compare the effect of metformin, a fixed combination of metformin and pioglitazone, or dapagliflozin on insulin resistance in patients with newly diagnosed type 2 diabetes. METHODS: In this 6-week randomized open-label trial, 58 patients were randomly assigned to insulin with metformin, a fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Rui, Yuan, Lu, Shen, Yun, Shen, Ziyang, Ding, Bo, Ma, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518260/ https://www.ncbi.nlm.nih.gov/pubmed/37753480 http://dx.doi.org/10.2147/DMSO.S423322

Ejemplares similares

Fixed‐dose combination therapy‐based protocol compared with free pill combination protocol: Results of a cluster randomized trial
por: Sanuade, Olutobi A., et al.
Publicado: (2023)

Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
por: Chen, Zhiwei, et al.
Publicado: (2019)

Safety of long-term use of linezolid: results of an open-label study
por: Vazquez, Jose A, et al.
Publicado: (2016)

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial
por: DeCensi, Andrea, et al.
Publicado: (2014)

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
por: Denys, Hannelore, et al.
Publicado: (2020)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Open-Label Extension Study Comparing Latanoprost 0.005% Without vs With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Shen Lee, Bridgitte, et al.
Publicado: (2022)

Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open‐Label, Randomized Study
por: Adkison, Kimberly, et al.
Publicado: (2017)

Cooling Anesthesia for Intravitreal Injection: Results of the Prospective Open-Label, Dose-Ranging COOL-1 Trial
por: Chao, Daniel L, et al.
Publicado: (2021)

An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer
por: Lim, Elgene, et al.
Publicado: (2022)

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
por: Hickish, Tamas, et al.
Publicado: (2022)

Safety and feasibility of breast lesion localization using magnetic seeds (Magseed): a multi-centre, open-label cohort study
por: Harvey, James R., et al.
Publicado: (2018)

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
por: Imanishi, Yasuo, et al.
Publicado: (2020)

Efficacy of tiotropium and indacaterol monotherapy and their combination on dynamic lung hyperinflation in COPD: a random open-label crossover study
por: Fujimoto, Keisaku, et al.
Publicado: (2017)

Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study
por: Zhang, Lin, et al.
Publicado: (2022)

Exploratory Phase II Multicenter, Open-Label, Clinical Trial of ST266, a Novel Secretome for Treatment of Persistent Corneal Epithelial Defects
por: Jeng, Bennie H., et al.
Publicado: (2022)

Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study
por: Hu, Zhihuang, et al.
Publicado: (2022)

Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study
por: Li, Jian, et al.
Publicado: (2022)

Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
por: Hubbard, Joleen M., et al.
Publicado: (2022)

Combination of Pioglitazone and Metformin Actions on Liver Lipid Metabolism in Obese Mice
por: Liu, Jieying, et al.
Publicado: (2023)

Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy
por: Derosa, Giuseppe, et al.
Publicado: (2007)

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial
por: Cortes, Javier, et al.
Publicado: (2015)

Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study
por: Kim, Jeong Mi, et al.
Publicado: (2020)

Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
por: Di Pierro, Francesco, et al.
Publicado: (2021)

Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT
por: Sohrevardi, Seyed Mojtaba, et al.
Publicado: (2016)

Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open‐Label, Phase Ib Study
por: Lin, Chia‐Chi, et al.
Publicado: (2020)

Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
por: Clemens, Michael R., et al.
Publicado: (2014)

Patient-directed vs. fixed-volume PEG for colonoscopy preparation: a randomized controlled trial
por: Zhang, Jixiang, et al.
Publicado: (2022)

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
por: Marth, Christian, et al.
Publicado: (2022)

Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
por: Burillon, Carole, et al.
Publicado: (2018)

OncoVee™-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study
por: Zhang, Baonan, et al.
Publicado: (2023)

Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study
por: Jiang, Haiping, et al.
Publicado: (2020)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
por: Plate, Tanja, et al.
Publicado: (2020)

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
por: Pohlmann, Paula R., et al.
Publicado: (2022)

Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear
por: Rini, Christopher James, et al.
Publicado: (2015)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021)

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study
por: Ali, Haris, et al.
Publicado: (2022)

Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
por: Lipplaa, Astrid, et al.
Publicado: (2023)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_482uv7dps621d9apm3d3dp8j02